Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial

Conditions: B-cell Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse Interventions: Drug: Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy Sponsors: Beijing GoBroad Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials